8.46
price up icon0.12%   0.01
after-market After Hours: 8.46
loading
Chimerix Inc stock is traded at $8.46, with a volume of 1.83M. It is up +0.12% in the last 24 hours and up +90.54% over the past month. Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
See More
Previous Close:
$8.45
Open:
$8.44
24h Volume:
1.83M
Relative Volume:
0.27
Market Cap:
$787.18M
Revenue:
$324.00K
Net Income/Loss:
$-82.10M
P/E Ratio:
-9.0968
EPS:
-0.93
Net Cash Flow:
$-69.18M
1W Performance:
+0.00%
1M Performance:
+90.54%
6M Performance:
+872.41%
1Y Performance:
+616.95%
1-Day Range:
Value
$8.44
$8.47
1-Week Range:
Value
$8.415
$8.47
52-Week Range:
Value
$0.75
$8.47

Chimerix Inc Stock (CMRX) Company Profile

Name
Name
Chimerix Inc
Name
Phone
919.806.1074
Name
Address
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC
Name
Employee
72
Name
Twitter
@chimerix
Name
Next Earnings Date
2025-03-12
Name
Latest SEC Filings
Name
CMRX's Discussions on Twitter

Compare CMRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CMRX
Chimerix Inc
8.46 787.18M 324.00K -82.10M -69.18M -0.93
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
495.42 127.22B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
689.50 75.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.45 35.94B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.43 31.38B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.84 26.84B 3.32B -860.46M -1.04B -8.32

Chimerix Inc Stock (CMRX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-23-23 Initiated Robert W. Baird Outperform
Sep-07-22 Initiated CapitalOne Overweight
Apr-29-21 Initiated Maxim Group Buy
Apr-23-21 Resumed Cowen Outperform
Mar-31-21 Initiated Jefferies Buy
Mar-31-21 Initiated Wedbush Outperform
Feb-14-18 Downgrade JP Morgan Neutral → Underweight
Feb-02-18 Initiated H.C. Wainwright Buy
Aug-09-16 Reiterated FBR Capital Mkt Perform
Feb-23-16 Downgrade Barclays Overweight → Equal Weight
Feb-23-16 Reiterated FBR Capital Mkt Perform
Feb-23-16 Downgrade Morgan Stanley Equal-Weight → Underweight
Feb-22-16 Downgrade Citigroup Buy → Neutral
Dec-29-15 Downgrade JP Morgan Overweight → Neutral
Dec-28-15 Downgrade FBR Capital Outperform → Mkt Perform
Dec-28-15 Reiterated Piper Jaffray Overweight
Dec-17-15 Initiated UBS Buy
Oct-05-15 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-03-15 Initiated Citigroup Buy
Aug-18-15 Initiated FBR Capital Outperform
Aug-06-15 Reiterated Brean Capital Buy
May-11-15 Reiterated Brean Capital Buy
Mar-04-15 Initiated Barclays Overweight
Feb-12-15 Reiterated Stifel Buy
Dec-31-14 Reiterated Brean Capital Buy
Jul-08-14 Resumed Brean Capital Buy
View All

Chimerix Inc Stock (CMRX) Latest News

pulisher
05:39 AM

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of Shareholders - GlobeNewswire Inc.

05:39 AM
pulisher
Mar 11, 2025

Kuehn Law Encourages BRDG, CMRX, WBA and SYTA Investors to Contact Law Firm - The Malaysian Reserve

Mar 11, 2025
pulisher
Mar 11, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (NasdaqTSVT), Bridge Investment Group Holdings Inc. (NYSEBRDG), Chimerix, Inc. (NasdaqCMRX), 180 Degree Capital Corp. (Nasda - Morningstar

Mar 11, 2025
pulisher
Mar 11, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX, WBA, BLUE on Behalf of Shareholders - Victoria Advocate

Mar 11, 2025
pulisher
Mar 10, 2025

CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisi - WICZ

Mar 10, 2025
pulisher
Mar 10, 2025

CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc.CMRX - Business Wire

Mar 10, 2025
pulisher
Mar 09, 2025

Why Chimerix, Inc. (CMRX) Soared Last Week - Insider Monkey

Mar 09, 2025
pulisher
Mar 07, 2025

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - EIN News

Mar 07, 2025
pulisher
Mar 07, 2025

Chimerix, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair - Bluefield Daily Telegraph

Mar 07, 2025
pulisher
Mar 07, 2025

CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders - EIN News

Mar 07, 2025
pulisher
Mar 07, 2025

HC Wainwright Reiterates “Neutral” Rating for Chimerix (NASDAQ:CMRX) - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Top Medical Stocks To Add to Your Watchlist – March 5th - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Jefferies Financial Group Reaffirms Hold Rating for Chimerix (NASDAQ:CMRX) - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals - Nasdaq

Mar 07, 2025
pulisher
Mar 07, 2025

Best Pharmaceutical Stocks To Watch Today – March 5th - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Wedbush Reaffirms “Neutral” Rating for Chimerix (NASDAQ:CMRX) - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio - MSN

Mar 06, 2025
pulisher
Mar 06, 2025

Jazz Offers To Buy Chimerix For $935M To Boost Oncology Portfolio - Barchart

Mar 06, 2025
pulisher
Mar 06, 2025

Chimerix downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance

Mar 06, 2025
pulisher
Mar 06, 2025

This MongoDB Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga

Mar 06, 2025
pulisher
Mar 06, 2025

Jazz Pharmaceuticals to acquire Chimerix for $935m - World Pharmaceutical Frontiers

Mar 06, 2025
pulisher
Mar 06, 2025

Jazz Pharma to acquire Chimerix for ~$935M in cash - MSN

Mar 06, 2025
pulisher
Mar 05, 2025

Jazz Pharmaceuticals bids for Chimerix in $935m deal - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

CrowdStrike reports Q4 beat, Jazz to acquire Chimerix: Morning Buzz - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz to Acquire Chimerix for $935M, Expanding Rare Oncology Portfolio - Genetic Engineering & Biotechnology News

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharmaceuticals to acquire Chimerix for $935 million By Investing.com - Investing.com Canada

Mar 05, 2025
pulisher
Mar 05, 2025

Chimerix brings a rare cancer drug to the $935M Jazz party - BioWorld Online

Mar 05, 2025
pulisher
Mar 05, 2025

Chimerix Stock Hold Rating: Limited Upside Due to Acquisition Offer Price Alignment - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc.CMRX - PR Newswire

Mar 05, 2025
pulisher
Mar 05, 2025

Chimerix’s alignment with FDA on submission drives $935M takeout by Jazz - BioCentury

Mar 05, 2025
pulisher
Mar 05, 2025

Biotech Stock Chimerix (Nasdaq: CMRX) Soars on Acquisition News - Investorideas.com newswire

Mar 05, 2025
pulisher
Mar 05, 2025

Cautious Outlook on Chimerix Amid Acquisition and Uncertainties in Drug Approval - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Strategic Acquisition and NDA Submission Boost Chimerix’s Market Potential - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Demystifying Chimerix: Insights From 4 Analyst Reviews - Benzinga

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Buys ChimerixA Good Deal To Make With Major Approval Catalyst In Play - Seeking Alpha

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharmaceuticals to Acquire Chimerix for $935M - USA Herald

Mar 05, 2025
pulisher
Mar 05, 2025

3 Firms Build Jazz Pharmaceuticals' $935M Chimerix Buy - Law360

Mar 05, 2025
pulisher
Mar 05, 2025

Chimerix deal represents ‘clear strategic fit’ for Jazz, says Stifel - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Jefferies Downgrades Chimerix to Hold From Buy, Price Target is $8.50 -March 05, 2025 at 12:31 pm EST - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz expands in oncology with $935M deal for Chimerix - BioPharma Dive

Mar 05, 2025
pulisher
Mar 05, 2025

North Carolina drugmaker sold in $935M deal - The Business Journals

Mar 05, 2025
pulisher
Mar 05, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders - Finansavisen

Mar 05, 2025
pulisher
Mar 05, 2025

Chimerix a Prime Acquisition Candidate for Jazz Pharmaceuticals Due to Dordaviprone, Wedbush Says - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharmaceuticals plc entered into a definitive agreement to acquire Chimerix, Inc. for approximately $930 million. - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharma aims to boost cancer drug pipeline with $935 million buyoutSan Francisco Business Times - The Business Journals

Mar 05, 2025
pulisher
Mar 05, 2025

Hold Rating Issued Amidst Chimerix Acquisition by Jazz Pharmaceuticals - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Jazz Pharma to expand oncology portfolio with buy of Chimerix - The Pharma Letter

Mar 05, 2025
pulisher
Mar 05, 2025

Chimerix surges on Jazz Pharma's $935 million buyout - TradingView

Mar 05, 2025

Chimerix Inc Stock (CMRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$35.01
price up icon 3.70%
$307.09
price up icon 0.88%
$32.85
price up icon 1.20%
$19.91
price up icon 7.62%
$100.31
price up icon 1.95%
biotechnology ONC
$249.84
price up icon 1.68%
Cap:     |  Volume (24h):